MacroGenics Stock (NASDAQ:MGNX)
Previous Close
$3.87
52W Range
$2.95 - $21.88
50D Avg
$3.55
200D Avg
$8.75
Market Cap
$232.07M
Avg Vol (3M)
$642.82K
Beta
2.07
Div Yield
-
MGNX Company Profile
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Performance
Peer Comparison
Ticker | Company |
---|---|
NGM | NGM Biopharmaceuticals, Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
CGEM | Cullinan Oncology, Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
TYRA | Tyra Biosciences, Inc. |
INZY | Inozyme Pharma, Inc. |
ANTX | AN2 Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
NKTX | Nkarta, Inc. |
PEPG | PepGen Inc. |
MOLN | Molecular Partners AG |
KZR | Kezar Life Sciences, Inc. |
PTGX | Protagonist Therapeutics, Inc. |